登录

Brattea Raises ¥100 Million in Extended Series B Round

Mailman 2021-04-13 09:06

魅丽纬叶
http://www.brattea.com/
企业数据由 动脉橙 提供支持
高血压介入类器械研发商 | D轮 | 运营中
中国-上海
2024-03-25
融资金额:数亿人民币
中平资本
查看

(VCBeat) Apr. 05, 2021 -- Shanghai Meili Weiye Medical Technology Co., Ltd. ("Brattea"), a domestic leader in neuro-radiofrequency ablation, announced that it had obtained a Series B+ financing of over 100 million yuan, led by Kuanping Capital. New investors include Hengxu Capital, Pudong Science & Technology Co., and Brosmed. Prior round investors include Northern Light Venture Capital, BioTrack Capital, and Sherpa Healthcare Partners.


This round of financing is the largest investment event in the renal denervation (RDN) sector in China so far.


Founded in 2013, Brattea specializes in the research, development and commercialization of RDN products. The company owns a number of world-leading patented technologies with independent intellectual property rights in this field. It also has close cooperation with well-known experts, universities and hospitals in China. Brattea has successfully developed a percutaneous intravascular radiofrequency nerve ablation platform for chronic disease treatment and management. It has taken a leading position in the field of minimally invasive treatment of hypertension both at home and abroad, and has made significant progress in multiple promising indications including cancer pain and diabetes.


Brattea plans to use the funds to accelerate clinical trials, expand its clinical and technical teams, consolidate its leading position in RDN, and build itself into a platform company based on neuro-radiofrequency ablation technology.


The RDN sector is one of the few subdivision tracks in the medical device industry where the leading domestic enterprises and the global leaders are still at the same starting line. Both in terms of product performance and clinical effect, the original products of Brattea have shown many advantages over the SPYRAL series of Medtronic's products, and are expected to become the "Best in Class" products worldwide in the future.


>>>>

About Kuanping Capital


Founded in 2016, Kuanping Capital is a healthcare dedicated private equity fund with offices in Beijing and Shanghai. They focus on attractive areas including Medtech, Healthcare Service, Biotech, and Digital Health. "Buy and Build" is Kuanping Capital's core philosophy. In addition to capital support, they work closely with management to integrate resources, improve operation efficiency and embrace new technology.


>>>>

About Hengxu Capital


Established on July 16, 2019, Hengxu Capital is SAIC Capital's parent fund management platform. While relying on the resources of SAIC, Hengxu Capital invests in strategic emerging industries such as advanced manufacturing, cutting-edge technology, big health, and big consumption. With the capital, it contributes to the development of SAIC's innovative industry chain and the improvement of SAIC's ecosystem. The current AUM of Heng Xu Capital is RMB 6.9 billion.

注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。
推荐阅读

TransCode Therapeutics,股份有限公司宣布拟公开发行普通股

GlobeNewswire 2024-07-23 04:07

FinnGen选择Azenta推进人群健康研究的个性化医疗

CISION 2024-07-23 04:05

Windtree Therapeutics宣布通过私募C系列优先股完成融资

GlobeNewswire 2024-07-23 04:05

Mailman

共发表文章3245篇

最近内容
查看更多
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

相关公司
查看更多

浦东科创

创业投资机构

立即沟通

魅丽纬叶

高血压介入类器械研发商

立即沟通

恒旭资本

私募股权投资机构

立即沟通
产业链接
查看更多